U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07943520) titled 'A Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic Function' on Nov. 11.

Brief Summary: This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with mild, and moderate hepatic impairment compared to participants with normal hepatic function.

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Hepatic Impairment

Intervention: DRUG: SYH2053

SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) ...